Characteristics of 41 ET patients and 38 matched controls of the cross-sectional study
| . | Patients . | Controls . |
|---|---|---|
| Age, y | 57 (46-66) | 57.5 (46-65) |
| Females, n (%) | 23 (56) | 26 (68) |
| Platelets, × 103/μL | 399 (335-649) | 212 (192-245)* |
| WBCs, μL | 6760 (5545-8652) | 6310 (4637-7280) |
| Hb, g/dL | 14 (13.4-15) | 13.4 (13-15) |
| MPV, fL | 10.1 (9.7-10.5) | 10.8 (10.4-11.3)* |
| PDW, fL | 11.9 (11-12.4) | 13.1 (12-14)* |
| IPF, % | 2.3 (1.9-3.1) | 2.6 (1.8-4.1) |
| Immature platelets, × 103/μL | 10.3 (6.3-16.4) | 5.7 (4.1-9.4)* |
| Glycocalicin, μg/mL | 8.1 (5.2-12.9) | 2.4 (1.3-3.3)* |
| GCI | 4.6 (3.5-6) | 2.6 (1.5-4)* |
| HU, n (%) | 23 (56) | NA |
| JAK-2 mutation, n (%) | 28 (68) | NA |
| Duration of aspirin therapy, mo | 42 (12-72) | NA |
| Serum TXB2, ng/mL | 13.6 (9.9-33) | ND |
| Serum PGE2, ng/mL | 0.68 (0.48-1.44) | ND |
| . | Patients . | Controls . |
|---|---|---|
| Age, y | 57 (46-66) | 57.5 (46-65) |
| Females, n (%) | 23 (56) | 26 (68) |
| Platelets, × 103/μL | 399 (335-649) | 212 (192-245)* |
| WBCs, μL | 6760 (5545-8652) | 6310 (4637-7280) |
| Hb, g/dL | 14 (13.4-15) | 13.4 (13-15) |
| MPV, fL | 10.1 (9.7-10.5) | 10.8 (10.4-11.3)* |
| PDW, fL | 11.9 (11-12.4) | 13.1 (12-14)* |
| IPF, % | 2.3 (1.9-3.1) | 2.6 (1.8-4.1) |
| Immature platelets, × 103/μL | 10.3 (6.3-16.4) | 5.7 (4.1-9.4)* |
| Glycocalicin, μg/mL | 8.1 (5.2-12.9) | 2.4 (1.3-3.3)* |
| GCI | 4.6 (3.5-6) | 2.6 (1.5-4)* |
| HU, n (%) | 23 (56) | NA |
| JAK-2 mutation, n (%) | 28 (68) | NA |
| Duration of aspirin therapy, mo | 42 (12-72) | NA |
| Serum TXB2, ng/mL | 13.6 (9.9-33) | ND |
| Serum PGE2, ng/mL | 0.68 (0.48-1.44) | ND |
Values are medians and IQR.
IPF indicates immature platelet fraction; MPV, mean platelet volume; PDW, platelet distribution width; Hb, hemoglobin; NA, not applicable; and ND, not determined (healthy controls were not on aspirin).
P < .001 versus patients.